Phase 1 Management Clinical Trials
28 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 28 trials
Recruiting
Phase 1
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
Weight Management
Gilead Sciences134 enrolled3 locationsNCT06562907
Not Yet Recruiting
Phase 1
A comparison of pain levels following injections of hypotonic saline, sterile water or normal saline: A randomised trial
sterile water injections for labour pain management
The University of Queensland90 enrolled1 locationACTRN12626000138381
Recruiting
Phase 1Phase 2
A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
Weight ManagementOverweight and/or Obesity
Hangzhou Sciwind Biosciences Co., Ltd.84 enrolled1 locationNCT07243171
Not Yet Recruiting
Phase 1
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of IPI-201 Administered Intravenously in Healthy Male Participants
Management of peri-operative pain
Isosceles Pharmaceuticals Australia Pty Ltd22 enrolled1 locationACTRN12625001213437
Recruiting
Phase 1
Phase I Study of XTL6001 Injection in Healthy and Obese Subjects
Weight Management in Adult Patients With Obesity or Overweight
Shanghai Xitaili Biomedicine Technology co., Ltd.80 enrolled1 locationNCT07205432
Recruiting
Phase 1
A Study of YP05002 in Healthy Participants
Weight Management
Yaopharma Co., Ltd.76 enrolled1 locationNCT07089823
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of (2S)-2-[17-(cyclopropylmethyl)-4, 5a-epoxy-3-hydroxy-6-methoxy-6a, 14-ethano-14a-morphinan-7a-yl]-3, 3-dimethylbutan-2-ol transdermal patch against the innovator (2S)-2-[17-(cyclopropylmethyl)-4, 5a-epoxy-3-hydroxy-6-methoxy-6a, 14-ethano-14a-morphinan-7a-yl]-3, 3-dimethylbutan-2-ol transdermal patch conducted under fasting conditions with the inclusion of a naltrexone block in healthy male and female volunteers
(2S)-2-[17-(cyclopropylmethyl)-4, 5a-epoxy-3-hydroxy-6-methoxy-6a, 14-ethano-14a-morphinan-7a-yl]-3, 3-dimethylbutan-2-ol is a partial opioid agonist indicated for the management of severe pain.
Zenith Technology Corporation Limited26 enrolled1 locationACTRN12622000133730
Completed
Phase 1
A prospective, open label study to evaluate the safety and pharmacokinetics of ML-004-ER under fed and fasted conditions in healthy adult volunteers
Management of patients with autism spectrum disorder
MapLight Therapeutics Inc12 enrolled1 locationACTRN12621000461897
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid tablets against the innovator (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid tablets conducted under fasting conditions in healthy male and female volunteers
(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid is used for the treatment of management of demonstrated thyroid hormone deficiency.
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12620000191998
Completed
Phase 1
An Ascending Dose Study of the Dexmedetomidine Transdermal System in Healthy Subjects
Acute Pain Management in postoperative setting
Clinical Network Services Pty Ltd80 enrolled1 locationACTRN12619000476134
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 1,1-Dimethyl-2-Phenylethylamine 40 mg capsule against the innovator 1,1-Dimethyl-2-Phenylethylamine 40 mg capsule conducted under fasting condition and at steady state in healthy male and female volunteers.
1,1-Dimethyl-2-Phenylethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12618000563268
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 1,1-Dimethyl-2-Phenylethylamine 15 mg capsule against the innovator 1,1-Dimethyl-2-Phenylethylamine 15 mg capsule conducted under fasting condition in healthy male and female volunteers.
1,1-Dimethyl-2-Phenylethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12618000423213
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 1,1-Dimethyl-2-Phenylethylamine capsule against the innovator 1,1-Dimethyl-2-Phenylethylamine capsule conducted under fasting condition in healthy male and female volunteers.
1,1-Dimethyl-2-Phenylethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12618000308291
Completed
Phase 1
A healthy volunteer study to test the safety and tolerability of a single dose of the Dexmedetomidine Transdermal System as well as how your body takes it in and disposes and breaks it down.
Acute Pain Management in postoperative setting
Clinical Network Services Pty Ltd36 enrolled1 locationACTRN12618000205235
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 1,1-Dimethyl-2-Phenylethylamine capsule against the innovator 1,1-Dimethyl-2-Phenylethylamine capsule conducted under fed condition in healthy male and female volunteers.
1,1-Dimethyl-2-Phenylethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction
Zenith Technology Corporation Limited20 enrolled1 locationACTRN12617001555347
Completed
Phase 1
A pilot randomised open-label taste-testing study to evaluate the acceptability of chocolate-based tramadol in children
Pain management in relation to surgery
Princess Margaret Hospital150 enrolled2 locationsACTRN12617001490369
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 15 mg alpha,alpha-dimethylphenethylamine tablet against the innovator 15 mg alpha,alpha-dimethylphenethylamine capsule conducted under fasting conditions in healthy male and female volunteers.
alpha,alpha-dimethylphenethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction.
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12617001384347
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of alpha,alpha-dimethylphenethylamine tablet against the innovator alpha,alpha-dimethylphenethylamine capsule conducted under fasting conditions and at steady state in healthy male and female volunteers.
alpha,alpha-dimethylphenethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction.
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12617001321336
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of alpha,alpha-dimethylphenethylamine tablet against the innovator alpha,alpha-dimethylphenethylamine capsule conducted under fed conditions in healthy male and female volunteers.
alpha,alpha-dimethylphenethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction.
Zenith Technology Corp Ltd24 enrolled1 locationACTRN12617001314314
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of alpha,alpha-dimethylphenethylamine tablet against the innovator alpha,alpha-dimethylphenethylamine capsule conducted under fasting conditions in healthy male and female volunteers.
alpha,alpha-dimethylphenethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction.
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12617001303336